Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1-2 Trial of Temozolomide and Hypofractionated Radiotherapy in Treatment of Supratentorial Glioblastoma Multiforme

NCT01120639 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT01120639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01120639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1-2 Trial of Temozolomide and Hypofractionated Radiotherapy in Treatment of Supratentorial Glioblastoma Multiforme
Lead sponsor
Stanford University
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2010
Completion date
November 15, 2020
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of brain and nervous system, glioblastoma, glioblastoma multiforme